We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Disney (DIS) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Disney (DIS - Free Report) is set to report third-quarter fiscal 2019 results on Aug 6.
Notably, the company’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, the average positive surprise being 6.6%.
In second-quarter fiscal 2019, earnings of $1.61 per share comfortably beat the Zacks Consensus Estimate by a couple of cents but declined 13% year over year.
Revenues of $14.92 billion increased 3% from the year-ago quarter and surpassed the consensus mark of $14.64 billion.
The Zacks Consensus Estimate for third-quarter fiscal 2019 earnings has been steady at $1.76 over the past 30 days. The figure indicates a decline of 5.9% from the year-ago quarter’s reported figure.
The consensus mark for revenues is pegged at $21.68 billion, implying growth of 42.4% from the year-ago period’s reported figure.
Let’s see how things are shaping up for this announcement.
Avenger’s Endgame Success to Aid Top-line
Marvel’s Avengers: Endgame released on April 26 broke box-office records, hitting the billion-dollar mark in just five days.
The movie collected $350 million domestically and $1.2 billion worldwide by its opening weekend and shattered the record of Avengers: Infinity War, which took 11 days to hit the billion-dollar level.
Most recently, Avengers: Endgame surpassed Avatar to become the highest-grossing film of all time.
Additionally, Disney’s Aladdin released on May 24 has passed the $1-billion benchmark. Per CNBC, Toy Story 4 is set for a similar record.
Notably, Disney overall has collected a record $7.67 billion at the global box office this year till date.
The phenomenal success of Avengers: Endgame must have driven Studio Entertainment segment’s top line in the to-be-reported quarter.
The Zacks Consensus Estimate for Studio Entertainment revenues is currently pegged at $4.76 billion, suggesting growth of 65.2% from the figure reported in the year-ago quarter.
DTC Investments to Hurt Profitability
Disney’s third-quarter fiscal 2019 profitability is likely to decline due to its ongoing investments in direct-to-consumer (DTC) businesses that now include Hulu, ESPN+ and the upcoming Disney+ streaming service.
Management expects DTC related investments to dent segment operating profit by almost $460 million.
What Our Model Says
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. Stocks with a Zacks Rank #4 or 5 (Sell-rated) are best avoided.
Disney has a Zacks Rank #3 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:
Cisco Systems (CSCO - Free Report) has an Earnings ESP of +1.53% and a Zacks Rank #2.
Discovery has an Earnings ESP of +5.05% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Disney (DIS) to Report Q3 Earnings: What's in the Cards?
Disney (DIS - Free Report) is set to report third-quarter fiscal 2019 results on Aug 6.
Notably, the company’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, the average positive surprise being 6.6%.
In second-quarter fiscal 2019, earnings of $1.61 per share comfortably beat the Zacks Consensus Estimate by a couple of cents but declined 13% year over year.
Revenues of $14.92 billion increased 3% from the year-ago quarter and surpassed the consensus mark of $14.64 billion.
The Zacks Consensus Estimate for third-quarter fiscal 2019 earnings has been steady at $1.76 over the past 30 days. The figure indicates a decline of 5.9% from the year-ago quarter’s reported figure.
The consensus mark for revenues is pegged at $21.68 billion, implying growth of 42.4% from the year-ago period’s reported figure.
The Walt Disney Company Price and EPS Surprise
The Walt Disney Company price-eps-surprise | The Walt Disney Company Quote
Let’s see how things are shaping up for this announcement.
Avenger’s Endgame Success to Aid Top-line
Marvel’s Avengers: Endgame released on April 26 broke box-office records, hitting the billion-dollar mark in just five days.
The movie collected $350 million domestically and $1.2 billion worldwide by its opening weekend and shattered the record of Avengers: Infinity War, which took 11 days to hit the billion-dollar level.
Most recently, Avengers: Endgame surpassed Avatar to become the highest-grossing film of all time.
Additionally, Disney’s Aladdin released on May 24 has passed the $1-billion benchmark. Per CNBC, Toy Story 4 is set for a similar record.
Notably, Disney overall has collected a record $7.67 billion at the global box office this year till date.
The phenomenal success of Avengers: Endgame must have driven Studio Entertainment segment’s top line in the to-be-reported quarter.
The Zacks Consensus Estimate for Studio Entertainment revenues is currently pegged at $4.76 billion, suggesting growth of 65.2% from the figure reported in the year-ago quarter.
DTC Investments to Hurt Profitability
Disney’s third-quarter fiscal 2019 profitability is likely to decline due to its ongoing investments in direct-to-consumer (DTC) businesses that now include Hulu, ESPN+ and the upcoming Disney+ streaming service.
Management expects DTC related investments to dent segment operating profit by almost $460 million.
What Our Model Says
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. Stocks with a Zacks Rank #4 or 5 (Sell-rated) are best avoided.
Disney has a Zacks Rank #3 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:
CACI International (CACI - Free Report) has an Earnings ESP of +4.02% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cisco Systems (CSCO - Free Report) has an Earnings ESP of +1.53% and a Zacks Rank #2.
Discovery has an Earnings ESP of +5.05% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>